Results 111 to 120 of about 6,497 (208)
Background: Previous studies had shown that patients with breast cancer have a high level of prostate-specific antigen (PSA). But there was not any study about the role of prostate-specific antigen in detection of breast cancer.
Gholamreza Mohajeri +2 more
doaj
Natural‐Inspired Engineered Microalgae With Selenium Enrichment Enabled Potent Anti‐Tumor Immunity
Se‐Ssp was engineered as a potent immunomodulator for activating innate immunity via the TLR and cGAS‐STING pathways, therefore converting “cold” tumors into “hot” tumors to achieve high efficacy and long‐term therapeutic outcomes. ABSTRACT Immunotherapy has shed light on clinical oncology for several decades.
Yuqi Yang +11 more
wiley +1 more source
Supramolecular Degraders: An Emerging Paradigm in Targeted Protein Degradation
Dynamic supramolecular assembly reshapes targeted protein degradation by coordinating modular degrader construction, delivery, functional integration, and intracellular assembly or activation across proteasomal, endosomal–lysosomal, and autophagy–lysosomal pathways.
Kongjun Liu +8 more
wiley +1 more source
ABSTRACT Platinum‐based chemotherapy resistance remains a major obstacle in gastric cancer (GC) treatment. Through integrated transcriptomic profiling of cisplatin‐resistant xenografts and pharmacogenomic interrogation of the NCI‐60 dataset, we identified Prohibitin‐2 (PHB2) as a previously unrecognized determinant of chemoresistance.
Liang Xu +10 more
wiley +1 more source
GSTM4 enhances the interaction between ACLY and the E3 ubiquitin ligase TRIM27, thereby increasing K48‐linked ubiquitination at the K554 site of ACLY and promoting its degradation. Consequently, GSTM4 regulates lipid synthesis, as well as the proliferation and metastasis of PCa cells, by modulating ACLY stability.
Kang‐Ping Xiong +11 more
wiley +1 more source
This review elucidates how cancer cell metabolic reprogramming—across glucose, lipid, amino acid, and nucleotide pathways—remodels the tumor microenvironment to suppress anti‐tumor immunity and promote immune escape. Targeting these metabolic axes offers promising strategies to overcome immunotherapy resistance and enhance cancer treatment.
Guoqing Xiang +5 more
wiley +1 more source
BNC2 exhibits context‐dependent opposing functions across multiple cancer types. This study reveals BNC2 as an oncogenic driver of melanoma proliferation and metastasis through transcriptional activation of PIK3CA. The natural compound TSN simultaneously degrades BNC2 and its oncogenic partner SMAD3 via CRBN‐dependent ubiquitination.
Hui Dai +7 more
wiley +1 more source
Leveraging Microphysiological Systems to Facilitate Neutrophil‐Based Cancer Immunotherapy
Microphysiological systems are emerging as powerful human‐relevant platforms for studying neutrophil biology in cancer. Current applications of spheroids, organoids, and organ‐on‐a‐chip models are reviewed, together with future opportunities in behaviorome profiling, multi‐omics integration, personalized medicine, immune crosstalk, and multi‐organ ...
Shuai Shao +2 more
wiley +1 more source
A novel hetero‐bivalent agent, 68Ga/177Lu‐FZ‐NF‐1, concurrently targets Nectin‐4 and FAP in triple‐negative breast cancer. It yields significant preclinical tumor regression and clinically identifies additional metastatic lesions missed by 18F‐FDG PET, demonstrating promising theranostic potential for personalized management.
Ye Li +13 more
wiley +1 more source
Targeted chimeric degraders engage extracellular or membrane proteins and endocytosable cell‐surface receptors, forming ternary complexes that induce receptor‐mediated internalization. Following endocytosis, post‐endocytic sorting—not internalization alone—determines target fate.
Ke Liu +6 more
wiley +1 more source

